TP53 Mutations Promote Immunogenic Activity in Breast Cancer

BACKGROUND: Although immunotherapy has recently achieved clinical successes in a variety of cancers, thus far there is no immunotherapeutic strategy for breast cancer (BC). Thus, it is important to discover biomarkers for identifying BC patients responsive to immunotherapy. TP53 mutations were often...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Oncol
Main Authors: Liu, Zhixian, Jiang, Zehang, Gao, Yingsheng, Wang, Lirui, Chen, Cai, Wang, Xiaosheng
Formato: Artigo
Idioma:Inglês
Publicado: Hindawi 2019
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6582869/
https://ncbi.nlm.nih.gov/pubmed/31275382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/5952836
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares